Key result
Omitting anthracycline from front-line treatment for diffuse large B-cell lymphoma in patients with cardiovascular comorbidities reduces the likelihood of cure.
Why the study?
Does the omission of anthracycline reduce cure in patients with diffuse large B-cell lymphoma and cardiovascular comorbidities?
Does the omission of anthracycline reduce cure in patients with diffuse large B-cell lymphoma and cardiovascular comorbidities?
Answers are grounded in this paper and cite their sources.
In patients with DLBCL and cardiovascular comorbidities, omitting anthracyclines from front-line therapy reduces the chance of cure.
Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogenous B-cell non-Hodgkin lymphoma (NHL) with varied clinical outcome following standard therapy [1,2]. Front-line chemoimmunotherapy, ...
No takes yet. Share an insight, caveat, or question.
Melani et al. (2021) studied this question. Omitting anthracycline from front-line treatment for diffuse large B-cell lymphoma in patients with cardiovascular comorbidities reduces the likelihood of cure.
Synapse has enriched 10 related papers. Consider them for comparative context: